Table 3

Types of most common adverse events reported to clinicians by new antifibrotic users

NintedanibPirfenidoneTotalP value
Adverse event, any; n (%)0.020*
 Yes62.0 (73.8%)86.0 (58.5%)148.0 (64.1%)
Liver function test abnormality n (%)0.140*
 Yes9.0 (10.7%)8.0 (5.4%)17.0 (7.4%)
Photosensitivity n (%)<0.001*
 Yes0.0 (0.0%)34.0 (23.1%)34.0 (14.7%)
Gastrointestinal complaints n (%)0.012*
 Yes39.0 (46.4%)44.0 (29.9%)83.0 (35.9%)
Anorexia n (%)0.349*
 Yes21.0 (25.0%)29.0 (19.7%)50.0 (21.6%)
Blood count abnormality n (%)0.449*
 Yes0.0 (0.0%)1.0 (0.7%)1.0 (0.4%)
Diarrhoea n (%)<0.001*
 Yes53.0 (63.1%)16.0 (10.9%)69.0 (29.9%)
  • *Pearson’s χ2 test.